KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas.
KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas.
复制标题
KRAS 基因突变在结直肠绒毛状腺瘤和原位癌中比在癌中更常见。
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
M. Sabbath‐Solitare
中科院分区：
文献类型：
--
作者：
P. Zauber;S. Marotta;M. Sabbath‐Solitare
我们评估了从绒毛腺瘤到结直肠癌的关键转变过程中KRAS基因突变的频率，以评估腺瘤是否比癌更频繁地含有KRAS突变。我们分析了来自多个患者的散发性绒毛状和管状绒毛状腺瘤、原位癌和原发性结直肠癌。进一步评估肿瘤的粘液状态和微卫星不稳定性。KRAS和微卫星分析采用标准PCR分子技术。134个腺瘤中有61.9%，84个原位癌中有67.8%，171个癌中只有31.6%存在KRAS突变。我们的研究清楚地表明，管绒毛状腺瘤和绒毛状腺瘤，以及原位癌的良性和恶性部分，比结直肠癌更容易包含体细胞KRAS基因突变。这种差异仅限于非黏液性肿瘤和微卫星稳定肿瘤。我们的数据支持一种可能性，即具有野生型KRAS基因的非黏液性和微卫星稳定性癌可能在其早期阶段发生KRAS基因突变，在进一步生长过程中突变丢失。
We have evaluated the frequency of KRAS gene mutations during the critical transition from villous adenoma to colorectal carcinoma to assess whether the adenomas contain a KRAS mutation more frequently than carcinomas. We analyzed sporadic villous and tubulovillous adenomas, in situ carcinomas, and primary colorectal carcinomas from multiple patients. The cancers were further evaluated for mucinous status and microsatellite instability. Standard PCR molecular techniques were used for KRAS and microsatellite analyses. A KRAS mutation was found in 61.9% of 134 adenomas, 67.8% of 84 in situ carcinomas, and just 31.6% of 171 carcinomas. Our study clearly demonstrates that tubulovillous and villous adenomas, as well as both the benign and malignant parts of in situ carcinomas, are statistically more likely to contain a somatic KRAS gene mutation than colorectal carcinomas. This difference is confined to the non-mucinous and the microsatellite stable tumors. Our data support the possibility that non-mucinous and microsatellite stable carcinomas with wild-type KRAS gene may have had a mutation in the KRAS gene during their earlier stages, with the mutation lost during further growth.
影响因子：
158.5
作者：
VOGELSTEIN, B;FEARON, ER;BOS, JL
通讯作者：
BOS, JL